0Q4U Stock Overview Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Novonesis A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for Novonesis Historical stock prices Current Share Price DKK 411.79 52 Week High DKK 547.40 52 Week Low DKK 344.90 Beta 0.54 1 Month Change 3.31% 3 Month Change -10.26% 1 Year Change 11.84% 3 Year Change -21.14% 5 Year Change 26.28% Change since IPO 335.38%
Recent News & Updates
Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024 Dec 17 Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025
Novonesis A/S Announces Board Changes Oct 21
First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023) Aug 28 Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024
Now 10% overvalued after recent price rise Jul 01 See more updates
Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024 Dec 17 Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025
Novonesis A/S Announces Board Changes Oct 21
First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023) Aug 28 Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024
Now 10% overvalued after recent price rise Jul 01
Now 21% overvalued after recent price rise Jun 20
Now 22% overvalued after recent price rise May 15
Novonesis Provides Sales Guidance for the Year 2024 May 03
Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023 May 01
Upcoming dividend of kr.2.00 per share Apr 24
Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023 Apr 09
Novonesis Provides Earnings Guidance for the Year 2024 Mar 23
Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West Mar 07
Novozymes A/S Announces Board Appointments Mar 05 Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024
New minor risk - Financial position Feb 09
New major risk - Shareholder dilution Feb 01 Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR). Jan 30
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR). Jan 29
Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024 Dec 14
Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment Nov 10
Novozymes Launches ProSilience™ HU58 Oct 28
Third quarter 2023 earnings released Oct 27
Now 21% undervalued after recent price drop Oct 13
Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023 Oct 13 Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure Oct 11
Now 20% undervalued after recent price drop Sep 19
Now 20% undervalued after recent price drop Aug 21
Second quarter 2023 earnings released Aug 10 Novozymes A/S Announces Change to the Executive Leadership Team
First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022) Apr 27
Upcoming dividend of kr.6.00 per share at 1.8% yield Feb 24
Independent Chairman recently bought kr.1.0m worth of stock Jan 30 Novozymes A/S Provides Earnings Guidance for the Year 2023
Full year 2022 earnings released Jan 26
Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors Jan 26
Investor sentiment deteriorated over the past week Dec 16 Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR). Dec 14
Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR). Dec 13
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released Nov 04
Novozymes A/S Provides Earnings Guidance for the Year 2022 Nov 04
Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study Oct 24
Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022 Oct 08
Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021) Aug 12
Novozymes A/S Provides Earnings Guidance for the Year 2022 Aug 11 Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023
Novozymes Extends the Lifetime of Textiles with Sustainable Innovation Jun 08
First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021) Apr 29
Less than half of directors are independent Apr 27
Novozymes A/S Raises Full-Year Financial Guidance for 2022 Apr 27
Upcoming dividend of kr.5.50 per share Mar 10
Full year 2021 earnings: Revenues in line with analyst expectations Feb 02
Novozymes A/S Provides Revenue Guidance for 2022 Feb 01
Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion. Dec 11
Third quarter 2021 earnings released Oct 27
Second quarter 2021 earnings released Aug 13
Novozymes A/S Provides Earnings Guidance for the Full Year 2021 Aug 12
First quarter 2021 earnings released Apr 28
Novozymes A/S Reaffirms Sales Guidance for the Year 2021 Apr 28
Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada Mar 16
Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development Mar 14 Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.
Upcoming Dividend of kr.5.25 Per Share Mar 05
New 90-day high: kr.383 Feb 08
Novozymes A/S Announces Executive Appointments, Effective April 2021 Feb 04
Full year 2020 earnings released Feb 04
Revenue misses expectations Feb 04
Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions Feb 02
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs. Jan 09
Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million Dec 20 Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021 Shareholder Returns 0Q4U GB Chemicals GB Market 7D -2.0% -3.2% -1.5% 1Y 11.8% -25.5% 3.5%
See full shareholder returns
Return vs Market: 0Q4U exceeded the UK Market which returned 3.5% over the past year.
Price Volatility Is 0Q4U's price volatile compared to industry and market? 0Q4U volatility 0Q4U Average Weekly Movement 2.8% Chemicals Industry Average Movement 5.8% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0Q4U has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0Q4U's weekly volatility (3%) has been stable over the past year.
About the Company Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Show more Novonesis A/S Fundamentals Summary How do Novonesis's earnings and revenue compare to its market cap? 0Q4U fundamental statistics Market cap DKK 190.21b Earnings (TTM ) DKK 2.11b Revenue (TTM ) DKK 22.71b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0Q4U income statement (TTM ) Revenue €3.04b Cost of Revenue €1.62b Gross Profit €1.42b Other Expenses €1.14b Earnings €282.79m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
Earnings per share (EPS) 0.61 Gross Margin 46.66% Net Profit Margin 9.29% Debt/Equity Ratio 18.1%
How did 0Q4U perform over the long term?
See historical performance and comparison Dividends
1.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 15:04 End of Day Share Price 2024/12/18 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Novonesis A/S is covered by 40 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Vitfell-Rasmussen ABG Sundal Collier Jyoti Prakash AlphaValue Carla Bänziger Bank Vontobel AG
Show 37 more analysts 
